A new gene test could identify which patients are likely to suffer more aggressive forms of rhabdomyosarcoma, and thus are in need of more intensive therapy.
Scientists have developed technology to mimic the real-life conditions that facilitate bone tumor growth, showing how the effect of an anticancer drug changes according to the forces experienced by the cells.
Ben Holland speaks to Francesca Lake, Managing Commissioning Editor: Ben Holland is a nationally known expert on oncology-specific consulting solutions in the USA.
We’ve been having a look back at what a great year 2014 was for Oncology Central this week and reviewing which of the year’s content you found most engaging.
Researchers from the Huntsman Cancer Institute at the University of Utah (UT, USA) have confirmed that a fusion gene causes alveolar soft-part sarcoma (ASPS).
This article focuses on the most recent developments in the therapy of advanced GIST that is resistant to standard therapies.
This review highlights a selection of presentations that were given at the ASCO 2014 Annual Meeting on the CNS and primary brain tumors.
This case report discusses a clinical investigation where the features of cancer-related TMAs (CR-TMAs) were studied and compared with patients suffering from idiopathic TTP.
A team of researchers at the Research Institute of the McGill University Health Centre (Montreal, Canada) have demonstrated that bisphosphonates, used to treat osteoporosis in postmenopausal women, could slow bone metastasis in breast cancer patients.
This commentary highlights the current lack of effective treatments for cancer cachexia, despite our increasing understanding of its management and pathophysiology.